What it is
ARIA means amyloid-related imaging abnormalities, a safety issue described in anti-amyloid Alzheimer treatment labeling and FDA communications.[1,2]
Why it matters
FDA communications describe ARIA-E as brain swelling or fluid buildup and recommend MRI monitoring around lecanemab treatment.[2]
What it affects
- Donanemab prescribing information includes a boxed warning for ARIA according to FDA approval information.[1]